35 participants
First-line Therapy With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor(EGFR-TKI) Combined With Trastuzumab Rezetecan for Advanced Non-small Cell Lung Cancer(NSCLC) Harboring EGFR Mutations Concomitant With Human Epidermal Growth Factor Receptor 2(HER2) Alterations
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2026-08-17
- Start Date:
- 2026-09-09
- Completion:
- 2029-03-31
Conditions
- Lung Cancer (NSCLC)
- EGFR Activating Mutation
- HER2
Interventions
- DRUG
No Results Yet